Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dbv Technologies SA is conducting a Phase 3 clinical trial titled ‘Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers).’ The study aims to evaluate the safety of the DBV712 250 mcg patch in young children with peanut allergies over a six-month period. This research is significant as it could lead to a new treatment option for peanut allergies in a vulnerable age group.
The intervention being tested is the DBV712 250 mcg epicutaneous patch, designed to deliver small doses of peanut protein through the skin to build tolerance in allergic children. A placebo patch is also used for comparison.
The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish the safety of the DBV712 patch.
The study began on June 24, 2025, with primary completion expected after six months. The last update was on August 5, 2025. These dates are crucial as they guide the timeline for potential market entry and investor expectations.
This clinical update could positively impact Dbv Technologies’ stock performance by boosting investor confidence in the company’s innovative approach to treating peanut allergies. The study’s progress may also influence the competitive landscape, as other companies in the allergy treatment sector monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.